Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Production method suitable for enzymatic synthesis of sitagliptin phosphate

A technology for sitagliptin phosphate and a production method is applied in the field of improvement of the production process for enzymatically synthesizing sitagliptin phosphate, and can solve the problems of unreachable salt formation and crystallization, long cycle, increased waste water and cost, and the like, To achieve the effect of saving production costs

Pending Publication Date: 2020-02-14
HUBEI HONGYUAN PHARMA
View PDF8 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Through the research on its process, it is found that: (1) the purification of enzymes will lead to low catalytic efficiency, long cycle, and a large increase in waste water and cost; A large number of other impurities (such as substrates, intermediates, coenzymes, protein fat-soluble impurities, etc.) are produced, resulting in later salt formation and crystallization that cannot meet the quality requirements of raw materials; (3) waste solvents (DMSO, isopropyl Alcohol) reuse plan
Other relevant literature and patent reports use bio-enzymatic synthesis of sitagliptin, but there is no consistent content with the process method reported in this patent

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Production method suitable for enzymatic synthesis of sitagliptin phosphate
  • Production method suitable for enzymatic synthesis of sitagliptin phosphate
  • Production method suitable for enzymatic synthesis of sitagliptin phosphate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0018] In order to make the purpose and technical solutions of the embodiments of the present invention more clear, the technical solutions of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Apparently, the described embodiments are some, not all, embodiments of the present invention. Based on the described embodiments of the present invention, all other embodiments obtained by persons of ordinary skill in the art without creative efforts shall fall within the protection scope of the present invention.

[0019] The following are examples:

[0020] A production method suitable for enzymatically synthesizing sitagliptin phosphate, comprising the following steps:

[0021] (1) Cultivate a batch of transaminase cells with catalytic activity in a 100L fermenter, and use a tubular centrifuge to obtain 4820g of bacterial sludge. Take a certain amount of bacterial sludge, add 5°C PBS solution to mix, an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a production method suitable for enzymatic synthesis of sitagliptin phosphate. The method is characterized by comprising the following steps: (1) carrying out fermentation culture on transaminase cells with catalytic activity, performing centrifuging to obtain bacterial sludge, performing crushing twice, and directly putting crushed powder into a reaction kettle to carry out catalytic reaction with a substrate, wherein the addition amount is 45-85 wt% (based on the amount of the bacterial sludge / the substrate); (2) using partially-recovered DMSO in the catalytic reaction, wherein the total impurity content is less than or equal to 5%, the specific gravity is required to be 1.0-1.1, and the ratio of the DMSO to added fresh DMSO is 1:(0.2-0.8); (3) adding ethyl acetate for extraction after adjusting the acidity to ensure that the impurity content in mother liquor is lower than 0.1%; and (4) adding recycled isopropanol (the content is 70%-90%) into a salifying reaction. Compared with common reported enzyme catalysis methods, the process method can ensure that the finished product meets the quality requirements of raw material medicines, saves the production cost to the maximum extent, and is suitable for large-scale production and application.

Description

technical field [0001] The invention belongs to the technical field of pharmacy, and in particular relates to an improved production process suitable for enzymatically synthesizing sitagliptin phosphate. Background technique [0002] Sitagliptin is the first DPP-IV inhibitor drug developed by Merck in the United States. It is a drug for the treatment of type 2 diabetes. Its medicinal form is sitagliptin phosphate monohydrate, which has the following structure : [0003] [0004] At present, the synthesis of sitagliptin in the international market is generally based on the total chemical synthesis method. During the production process, noble metal catalytic hydrogenation is used under high temperature and high pressure conditions. The catalyst is not easy to recycle, and the operation risk factor is high. Difficulty is big, is difficult to separate, and yield is low, causes cost higher. As Merck first developed the route of synthesizing sitagliptin by transaminase method...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12P17/18
CPCC12P17/182
Inventor 叶质强王心洁冯露鄂松
Owner HUBEI HONGYUAN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products